# Flow Cytometry Core

> **NIH NIH P30** · JOSLIN DIABETES CENTER · 2024 · $284,346

## Abstract

FLOW CYTOMETRY CORE: Abstract
The primary objective of the Joslin Diabetes Research Center (DRC) Flow Cytometry Core is to provide state-
of-the-art equipment and expertise for quantitative phenotyping of cells and for isolating pure populations of cells
from complex tissues. These approaches enable diabetes and metabolism investigators to study the
development and cellular physiology of pancreatic islet, muscle, and adipose cells, as well as the inflammatory
cells that contribute to autoimmune destruction of pancreatic beta cells, and to elucidate mechanisms in the
pathogenesis of diabetic retinopathy, nephropathy and atherosclerosis. Services of this Core enable
characterization of cellular phenotypes and rapid isolation of well-defined, pure, populations of live cells. Cell
sorting technology is continuously evolving and improving, enabling new approaches to address key questions
in diabetes research. In addition to continually updating equipment to offer cutting edge cell sorting technology
to its users, the Core provides outstanding expertise through consultations and educational activities. During the
past cycle, the Core was heavily used by diabetes investigators in the Joslin research base and the broader
Boston diabetes research community, and use of Core services led to high impact publications that advanced
the field. To meet the evolving needs of the research base, the Core acquired a new state-of-the-art flow
cytometer (Becton Dickinson LSRFortessa) and an Ellispot reader, both of which are now heavily used. In
addition, Core personnel provided training and education to users and carried out developmental research to
improve methods. In the next cycle in collaboration with the Molecular Phenotyping and Genotyping Core, the
Flow Cytometry Core will offer CITE-seq, an approach in which staining and flow cytometric analysis and
separation of cells is performed up-front of single cell RNA sequencing and combined with DNA-barcoded
antibodies that provide highly quantitative data on cell surface protein expression. CITE-seq will vastly expand
the ability to phenotype markers simultaneous with unbiased gene expression analysis in cells of relevance to
diabetes and metabolic disease. In sum, the Flow Cytometry Core provides critical equipment and expertise to
advance our understanding of the pathophysiology of diabetes and its complications, and ultimately develop
novel treatments and a cure for the disease and its complications.

## Key facts

- **NIH application ID:** 10847348
- **Project number:** 5P30DK036836-38
- **Recipient organization:** JOSLIN DIABETES CENTER
- **Principal Investigator:** AMY JO WAGERS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $284,346
- **Award type:** 5
- **Project period:** 1997-02-15 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10847348

## Citation

> US National Institutes of Health, RePORTER application 10847348, Flow Cytometry Core (5P30DK036836-38). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10847348. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*